Tianjin Medical Unversity Second Hospital | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive	Advanced Refractory Solid Tumors; EGFR Gene Overexpression	Recruiting	Phase 2	2026-07-17		NCT07712029
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Recruiting	Phase 2	2025-09-18		NCT07179783
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors	Solid Cancers	Recruiting	Phase 2	2025-09-12		NCT07170293
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)	Next-generation Sequencing; Precision Medicine; Solid Tumor, Adult	Recruiting	Phase 1 / Phase 2	2025-03-26		NCT06895733
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion	Precision Medicine; Solid Tumor	Recruiting	Phase 2	2024-12-18		NCT06739395
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure	Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Recruiting	Phase 1 / Phase 2	2024-10-29		NCT06663007